What is the standard insulin sliding‑scale regimen (regular insulin) for a patient on metformin 1000 mg twice daily and sitagliptin 50 mg twice daily, including glucose‑based correction doses, timing, and monitoring recommendations?

Sliding Scale Insulin Alone Should NOT Be Used as Primary Therapy

For a patient on metformin 1000 mg BID and sitagliptin 50 mg BID who develops hyperglycemia requiring insulin, you should initiate correctional (sliding scale) insulin ONLY as a temporary measure, with prompt transition to scheduled basal-bolus insulin if ≥2 blood glucose readings exceed 180 mg/dL within 24 hours 1.

Why Sliding Scale Insulin Alone Fails

The evidence is unequivocal: sliding scale insulin (SSI) as monotherapy is ineffective and outdated. Research demonstrates SSI fails to achieve target glucose control in 84-98% of hospitalized patients 2, 3. Basal-bolus regimens consistently outperform SSI in randomized trials, reducing complications including wound infections, pneumonia, bacteremia, and renal/respiratory failure 4.

Recommended Approach for Your Patient

Initial Strategy (If Mild Hyperglycemia)

• Continue metformin and sitagliptin (these can be safely continued in hospitalized patients with stable renal function) 5
• Add correctional insulin only using regular insulin before meals and at bedtime
• Target glucose range: 100-180 mg/dL 1

Standard Correctional Insulin Scale (Regular Insulin)

Use this scale before meals and at bedtime:

• BG 180-220 mg/dL: 2-4 units
• BG 221-260 mg/dL: 4-6 units
• BG 261-300 mg/dL: 6-8 units
• BG 301-350 mg/dL: 8-10 units
• BG >350 mg/dL: 10-12 units and notify physician

Critical timing: Administer regular insulin 30 minutes before meals, NOT at mealtime 6.

Mandatory Transition to Scheduled Insulin

If ≥2 point-of-care glucose readings ≥180 mg/dL occur within 24 hours on correctional insulin alone, you MUST add scheduled basal insulin 1. This is a strong recommendation from the 2022 Endocrine Society guidelines.

Basal-Plus Regimen (Preferred Next Step)

When transitioning from SSI:

• Basal insulin: 0.1-0.25 units/kg/day (given once daily, typically at bedtime)
• Continue correctional insulin before meals for glucose >180 mg/dL
• Monitor: Check glucose before meals and at bedtime (4 times daily)

For a 70 kg patient, this equals approximately 7-18 units of basal insulin daily.

Full Basal-Bolus Regimen (If Eating Regular Meals)

If persistent hyperglycemia continues:

• Total daily dose: 0.3-0.5 units/kg/day 4
• Split: 50% as basal insulin (once or twice daily), 50% as rapid-acting insulin divided before three meals
• Plus: Correctional doses with each meal

For a 70 kg patient: Total 21-35 units daily (approximately 10-18 units basal, 3-6 units before each meal, plus corrections).

Monitoring Protocol

• Frequency: Before each meal and at bedtime (minimum 4 times daily)
• Target range: 100-180 mg/dL 1
• Hypoglycemia threshold: <70 mg/dL requires immediate treatment and insulin dose reduction
• Document: All glucose values, insulin doses, and timing meticulously (documentation failures occur in ~30% of SSI cases) 2

Critical Caveats

Hypoglycemia risk: Basal-bolus insulin carries 4-6 times higher hypoglycemia risk than SSI alone 4. However, SSI's ineffectiveness at controlling hyperglycemia poses greater overall harm. Mitigate this by:

• Using lower initial doses (0.1-0.25 units/kg for basal-plus approach)
• Reducing doses by 10-20% if patient has poor oral intake
• Avoiding doses in elderly (>65 years) or those with renal impairment without careful monitoring 4

Metformin considerations: Verify eGFR >30 mL/min/1.73m² before continuing metformin. Discontinue if eGFR <30 or if patient requires iodinated contrast 5.

Never use premixed insulin (70/30) in the hospital—it carries unacceptably high hypoglycemia rates 4.

Bottom Line Algorithm

1. Day 1: Start correctional insulin only with continued oral agents
2. If ≥2 readings ≥180 mg/dL in 24 hours: Add basal insulin 0.1-0.25 units/kg/day
3. If still uncontrolled: Advance to full basal-bolus regimen 0.3-0.5 units/kg/day
4. Never continue SSI alone beyond 24-48 hours if hyperglycemia persists

The 2022 Endocrine Society guidelines 1 and 2021 Lancet guidelines 4 both explicitly recommend against SSI monotherapy, making this a clear evidence-based mandate for practice change.